Xenon Pharmaceuticals Inc.
XENE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582313
In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 2 open-market purchases and 1 sale; 285 institutions reported holding it in 13F filings for Q3 2026, worth $3.76B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $345.9M (4612.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Revenue | $7.50M | – | – | $9.43M | $18.4M |
| Operating expenses | $380.6M | $279.3M | $214.1M | $138.6M | $97.4M |
| Research and development | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M |
| Selling, general and administrative | $79.6M | $68.9M | $46.5M | $32.8M | $22.0M |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M |
| Income tax | $1.02M | -$4.09M | -$292.0K | $118.0K | -$6.00K |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$125.4M | -$78.9M |
| EPS, basic | $-4.36 | $-3.01 | $-2.73 | $-2.06 | – |
| EPS, diluted | $-4.36 | $-3.01 | $-2.73 | $-2.06 | – |
| Weighted shares, basic | 79.3M | 77.9M | 66.9M | 60.5M | – |
| Weighted shares, diluted | 79.3M | 77.9M | 66.9M | 60.5M | – |
| Margins and growth | |||||
| Operating margin | -4974.3% | – | – | -1368.9% | -428.4% |
| Net margin | -4612.1% | – | – | -1328.9% | -427.8% |
| Revenue growth, year over year | – | – | – | −48.8% | −42.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Cash and equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M |
| Short-term investments | $349.7M | $484.2M | $489.4M | $534.8M | $376.1M |
| Accounts receivable | – | $1.47M | $874.0K | $986.0K | $2.77M |
| Total current assets | $560.6M | $635.3M | $645.0M | $600.3M | $559.0M |
| Property, plant and equipment | $8.72M | $10.3M | $9.65M | $6.50M | $4.47M |
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M |
| Total current liabilities | $41.8M | $35.6M | $27.3M | $22.7M | $14.3M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M |
| Shareholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Operating cash flow | -$279.1M | -$181.4M | -$145.3M | -$98.4M | -$69.5M |
| Capital expenditures | $799.0K | $3.08M | $5.62M | $2.89M | $2.05M |
| Free cash flow | -$279.9M | -$184.5M | -$150.9M | -$101.3M | -$71.6M |
| Depreciation and amortization | $2.54M | $2.56M | $3.54M | $1.62M | $906.0K |
| Stock-based compensation | $53.7M | $50.7M | $32.4M | $20.4M | $10.0M |
| Investing cash flow | $218.0M | $165.0M | -$117.2M | -$296.0M | -$246.8M |
| Financing cash flow | $117.1M | $12.1M | $353.5M | $278.5M | $447.5M |
| Net change in cash | $56.5M | -$5.93M | $91.4M | -$118.4M | $130.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 716.1% | – | – | 216.0% | 54.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 98.3M | +27.2% | SEC |
| Aug 3, 2026 | 96.8M | +25.6% | SEC |
| May 4, 2026 | 96.7M | +26.0% | SEC |
| Feb 23, 2026 | 83.2M | +8.7% | SEC |
| Oct 30, 2025 | 77.3M | +1.4% | SEC |
| Aug 7, 2025 | 77.1M | +1.8% | SEC |
| May 8, 2025 | 76.7M | +1.7% | SEC |
| Feb 24, 2025 | 76.5M | +1.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.